Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay.

Pub Date : 2024-02-01 Epub Date: 2023-06-01 DOI:10.5546/aap.2023-02992.eng
Ana V González Castro, Verónica Sande, Lorena V Pardo Casaretto, Stella I Gutiérrez Rodríguez
{"title":"Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay.","authors":"Ana V González Castro, Verónica Sande, Lorena V Pardo Casaretto, Stella I Gutiérrez Rodríguez","doi":"10.5546/aap.2023-02992.eng","DOIUrl":null,"url":null,"abstract":"<p><p>Antiretroviral (ARV) drug resistance is a public health issue. Resistance has also been observed in the case of integrase strand transfer inhibitors (INSTIs) used in pediatrics. The objective of this article is to describe 3 cases of INSTI resistance. These are the cases of 3 children with vertically-transmitted human immunodeficiency virus (HIV). They were started on ARVs as infants and preschoolers, with poor treatment adherence, and had different management plans due to associated comorbidities and virological failure due to resistance. In the 3 cases, resistance developed rapidly as a result of virological failure and INSTI involvement. Treatment adherence should be monitored so that any increase in viremia can be detected early. Virological failure in a patient treated with raltegravir forces to a rapid change in ARV therapy because its continued use may favor new mutations and resistance to second-generation INSTIs.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5546/aap.2023-02992.eng","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Antiretroviral (ARV) drug resistance is a public health issue. Resistance has also been observed in the case of integrase strand transfer inhibitors (INSTIs) used in pediatrics. The objective of this article is to describe 3 cases of INSTI resistance. These are the cases of 3 children with vertically-transmitted human immunodeficiency virus (HIV). They were started on ARVs as infants and preschoolers, with poor treatment adherence, and had different management plans due to associated comorbidities and virological failure due to resistance. In the 3 cases, resistance developed rapidly as a result of virological failure and INSTI involvement. Treatment adherence should be monitored so that any increase in viremia can be detected early. Virological failure in a patient treated with raltegravir forces to a rapid change in ARV therapy because its continued use may favor new mutations and resistance to second-generation INSTIs.

分享
查看原文
垂直传播人类免疫缺陷病毒感染儿童对整合酶抑制剂的抗药性:乌拉圭的首例病例。
抗逆转录病毒(ARV)耐药性是一个公共卫生问题。儿科使用的整合酶链转移抑制剂(INSTIs)也出现了耐药性。本文旨在描述 3 例 INSTI 耐药性病例。这是 3 例垂直传播人类免疫缺陷病毒(HIV)的儿童病例。他们从婴儿和学龄前儿童开始接受抗逆转录病毒药物治疗,治疗依从性差,由于相关合并症和耐药导致的病毒学失败,他们的治疗方案各不相同。在这 3 个病例中,由于病毒学失败和 INSTI 的参与,耐药性发展迅速。应监测治疗的依从性,以便及早发现病毒血症的增加。使用拉替拉韦治疗的患者如果出现病毒学失败,就必须迅速更换抗逆转录病毒疗法,因为继续使用拉替拉韦可能会产生新的突变,并对第二代 INSTI 产生耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信